Efficacy of a combination of O-RADS, CEUS, and CA125, in identification of ovary-adnexal malignant lesions

To evaluate the efficacy of a combination of Ovarian-Adnexal Reporting and Data System (O-RADS), contrast-enhanced ultrasound (CEUS), and cancer antigen 125 (CA125) in identifying malignant ovarian-adnexal lesions and improving diagnostic accuracy, providing a reliable reference for the evaluation and management of ovarian-adnexal malignancies to enhance patient prognosis. The study analyzed the diagnostic performance of O-RADS alone and in combination with CEUS and CA125 for distinguishing between benign and malignant ovarian-adnexal lesions. Sensitivity, specificity, accuracy, and Kappa values were calculated to assess the efficacy of these diagnostic approaches. O-RADS alone showed a diagnostic sensitivity of 88.24%, specificity of 80.77%, and accuracy of 82.61% (Kappa = 0.719). When combined with CEUS, the diagnostic accuracy and Kappa value significantly improved. The combination of O-RADS, CEUS, and CA125 further enhanced the diagnostic performance, achieving sensitivity, specificity, and accuracy of 82.35%, 98.08%, and 94.20%, respectively (Kappa = 0.804). The combination of O-RADS, CEUS, and CA125 significantly improves the diagnostic accuracy of ovarian-adnexal malignant lesions, providing new clinical references for the evaluation and management of ovarian-adnexal malignancies and contributing to better patient prognosis.